CLIMB BIO, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-06-30: Study NCT07564596; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Recruiting.
- 2025-12-02: Study NCT07248865; Company role Lead sponsor; Phase Phase 1; Status Recruiting.
- 2025-08-25: Study NCT07096843; Company role Lead sponsor; Phase Phase 2; Status Recruiting.
- 2025-08-11: Study NCT07090655; Company role Lead sponsor; Phase Early Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | NCT07564596 A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | Lead sponsor | Phase 1, Phase 2 | Recruiting | Systemic Lupus Erthematosus | 30 | 2027-09 |
| 2025-12-02 | NCT07248865 A Phase 1 Study of CLYM116 in Normal Healthy Volunteers | Lead sponsor | Phase 1 | Recruiting | Healthy Volunteers | 48 | 2026-09 |
| 2025-08-25 | NCT07096843 A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy | Lead sponsor | Phase 2 | Recruiting | Primary Membranous Nephropathy | 45 | 2027-10 |
| 2025-08-11 | NCT07090655 A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers | Lead sponsor | Early Phase 1 | Completed | Healthy Volunteers | 30 | 2026-04-07 |
| 2025-07-10 | NCT07011043 A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | Lead sponsor | Phase 1 | Recruiting | Systemic Lupus Erythematosus | 30 | 2027-04 |
| 2025-06-30 | NCT07043946 A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) | Lead sponsor | Phase 1, Phase 2 | Recruiting | Immune Thrombocytopenia (ITP); ITP; Biologics; Monoclonal; Anti-CD19 | 24 | 2028-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |